Survival Benefit Continues With Encorafenib Plus Binimetinib in BRAF V600E+ Melanoma

Source: Targeted Oncology, May 2020

Encorafenib (Braftovi) plus binimetinib (Mektovi) show sustained overall survival (OS) and progression-free survival (PFS) benefit in patients with BRAF V600–mutant melanoma, according to updated findings from the COLUMBUS (NCT01909453) study, presented in a poster at the 2020 American Society of Clinical Oncology Virtual Scientific Program.1

The 2-part, phase 3 trial compared the combination of encorafenib and binimetinib versus encorafenib or vemurafenib (Zelboraf) in 577 patients enrolled across 28 countries and from 162 hospitals between December 2013 and November 2015.

In part 1, patients with unresectable or locally advanced or metastatic melanoma who were treatment naïve or progressed after prior first-line immunotherapy with a BRAF V600 mutation were equally randomized into 3 arms: encorafenib (450 mg once daily) and binimetinib (45 mg twice a day); vemurafenib (960 mg twice a day); or encorafenib (300 mg once daily).2

READ THE ORIGINAL FULL ARTICLE